Skip to main content
SpringerLink
Log in

Myxoid Liposarcoma: How to Stage and Follow

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Myxoid liposarcoma (MLPS) is a rare soft tissue sarcoma, with propensity to metastasize to locations such as soft tissue and bone. Thus, whole-body MRI should be a consideration as part of staging for patients with a new diagnosis of MLPS since PET and CT may not identify extrapulmonary disease. Surveillance imaging should be tailored, with consideration of more frequent and longer duration of monitoring for large tumors or tumors with round cell component. This review focuses on studies evaluating imaging in MLPS as well as recent publications on survival and prognostic tools in MLPS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed. Vol. 3). https://publications.Iarc.fr/588.

  2. Powers MP, et al. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol. 2010;23(10):1307–15.

    Article  CAS  PubMed  Google Scholar 

  3. Antonescu CR, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7(12):3977–87.

    CAS  PubMed  Google Scholar 

  4. Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol. 1996;20(2):171–80.

    Article  CAS  PubMed  Google Scholar 

  5. Moreau LC, et al. Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol. 2012;19(4):1081–8.

    Article  PubMed  Google Scholar 

  6. Schwab JH, et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer. 2007;110(8):1815–22.

    Article  PubMed  Google Scholar 

  7. Shinoda Y, et al. Prognostic factors of metastatic myxoid liposarcoma. BMC Cancer. 2020;20(1):883.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Setsu N, et al. Primary retroperitoneal myxoid liposarcomas. Am J Surg Pathol. 2016;40(9):1286–90.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dürr HR, et al. Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. BMC Cancer. 2018;18(1):304.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lansu J, et al. Time trends and prognostic factors for overall survival in myxoid liposarcomas: a population-based study. Sarcoma. 2020;2020:2437850. At over 900 patients, this is among the largest retrospective studies focused on myxoid liposarcoma and included a long interval of follow up.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Amin MB, et al. AJCC Cancer Staging Manual (Eighth Edition). American Joint Commission on Cancer: Springer International Publishing; 2017.

    Book  Google Scholar 

  12. Gronchi A, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(11):1348–65.

    Article  CAS  PubMed  Google Scholar 

  13. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Soft tissue sarcoma Version 2. 2022. Accessed January 12, 2023.

    Google Scholar 

  14. Lunn BW, et al. (18)F-FDG PET/CT and MRI features of myxoid liposarcomas and intramuscular myxomas. Skeletal Radiol. 2018;47(12):1641–50.

    Article  PubMed  Google Scholar 

  15. Stevenson JD, et al. Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease. Eur J Surg Oncol. 2016;42(4):574–80.

    Article  CAS  PubMed  Google Scholar 

  16. Gorelik N, et al. Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. Skeletal Radiol. 2018;47(3):369–79. This study showed that whole-body MRI detected metastasis before development of symptoms or identification on CT. It followed patients over a ten-year period.

    Article  PubMed  Google Scholar 

  17. Seo SW, et al. Feasibility of whole-body MRI for detecting metastatic myxoid liposarcoma: a case series. Orthopedics. 2011;34(11):e748–54.

    Article  PubMed  Google Scholar 

  18. Hoffman A, et al. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013;119(10):1868–77.

    Article  CAS  PubMed  Google Scholar 

  19. Pollack SM, et al. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020;9(13):4593–602.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Pasquali S, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022;128(1):85–93.

    Article  CAS  PubMed  Google Scholar 

  21. Pasquali S, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51–60.

    Article  CAS  PubMed  Google Scholar 

  22. Kamalapathy PN, et al. Development of machine learning model algorithm for prediction of 5-year soft tissue myxoid liposarcoma survival. J Surg Oncol. 2021;123(7):1610–7.

    Article  PubMed  Google Scholar 

  23. Kuyumcu G, et al. Quantification of fat content in lipid-rich myxoid liposarcomas with MRI: a single-center experience with survival analysis. Skeletal Radiol. 2018;47(10):1411–7.

    Article  PubMed  Google Scholar 

  24. Crombé A, et al. Can radiomics improve the prediction of metastatic relapse of myxoid/round cell liposarcomas? Eur Radiol. 2020;30(5):2413–24.

    Article  PubMed  Google Scholar 

  25. Wilson DAJ, et al. Designing a rational follow-up schedule for patients with extremity soft tissue sarcoma. Ann Surg Oncol. 2020;27(6):2033–41. This study reviewed over 1,000 patients with extremity STS and created a practical guideline for surveillance based on tumor size and grade.

    Article  PubMed  Google Scholar 

  26. Glasbey JC, et al. The impact of postoperative radiological surveillance intensity on disease free and overall survival from primary retroperitoneal, abdominal and pelvic soft-tissue sarcoma. Eur J Surg Oncol. 2021;47(7):1771–7.

    Article  CAS  PubMed  Google Scholar 

  27. Visgauss JD, et al. Staging and surveillance of myxoid liposarcoma: follow-up assessment and the metastatic pattern of 169 patients suggests inadequacy of current practice standards. Ann Surg Oncol. 2021;28(12):7903–11.

    Article  PubMed  Google Scholar 

  28. Gouin F, et al. Early detection of multiple bone and extra-skeletal metastases by body magnetic resonance imaging (BMRI) after treatment of Myxoid/Round-Cell Liposarcoma (MRCLS). Eur J Surg Oncol. 2019;45(12):2431–6.

    Article  PubMed  Google Scholar 

  29. Bignotti B, et al. Magnetic Resonance Imaging or Ultrasound in Localized Intermediate- or High-Risk Soft Tissue Tumors of the Extremities (MUSTT): final results of a prospective comparative trial. Diagnostics (Basel). 2022;12(2):411.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Thanh P. Ho MD

Authors
  1. Thanh P. Ho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thanh P. Ho MD.

Ethics declarations

Conflict of Interest

The author do not have any potential conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ho, T.P. Myxoid Liposarcoma: How to Stage and Follow. Curr. Treat. Options in Oncol. 24, 292–299 (2023). https://doi.org/10.1007/s11864-023-01064-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01064-5

Keywords

Search

Navigation